Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma | Journal for ImmunoTherapy of Cancer
Cancers | Free Full-Text | Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Therapeutic options for targeting myeloma epitopes, in this case, BCMA;... | Download Scientific Diagram
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | Nature Communications
Effective anti-BCMA retreatment in multiple myeloma - ScienceDirect
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma - NCI
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
Frontiers | Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma - ScienceDirect
B-Cell Maturation Antigen | Research | BMS Science | HCP Site
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector: Molecular Therapy
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells: Molecular Therapy - Methods & Clinical Development
B cell maturation antigen (BCMA)-based immunotherapies with multiple... | Download Scientific Diagram
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | bioRxiv
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia
CIMB | Free Full-Text | sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma | Journal of Clinical Oncology
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages: Molecular Therapy - Methods & Clinical Development
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma | PNAS
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia - ScienceDirect
Frontiers | Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
